Stonehill Capital Management’s Sanofi Contingent Value Rights GCVRZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-54,410,668
| Closed | -$46.8M | – | 34 |
|
|
2019
Q4 | $46.8M | Buy |
54,410,668
+720,793
| +1% | +$553K | 15.92% | 3 |
|
|
2019
Q3 | $30.1M | Buy |
53,689,875
+451,800
| +0.8% | +$243K | 8.18% | 3 |
|
|
2019
Q2 | $27.7M | Buy |
53,238,075
+4,161,166
| +8% | +$2.08M | 7.93% | 3 |
|
|
2019
Q1 | $22.1M | Buy |
49,076,909
+327,388
| +0.7% | +$153K | 6.65% | 3 |
|
|
2018
Q4 | $23.4M | Buy |
48,749,521
+5,496,160
| +13% | +$2.73M | 10.91% | 2 |
|
|
2018
Q3 | $22.9M | Hold |
43,253,361
| – | – | 8.69% | 3 |
|
|
2018
Q2 | $21.6M | Hold |
43,253,361
| – | – | 8.47% | 3 |
|
|
2018
Q1 | $18.3M | Hold |
43,253,361
| – | – | 7.85% | 3 |
|
|
2017
Q4 | $16.4M | Buy |
43,253,361
+3,598,346
| +9% | +$1.37M | 6.7% | 5 |
|
|
2017
Q3 | $14.3M | Hold |
39,655,015
| – | – | 5.68% | 4 |
|
|
2017
Q2 | $15.1M | Buy |
39,655,015
+6,252,861
| +19% | +$2.55M | 5.69% | 4 |
|
|
2017
Q1 | $15M | Buy |
33,402,154
+1,339,709
| +4% | +$588K | 6.58% | 6 |
|
|
2016
Q4 | $12.2M | Buy |
32,062,445
+10,332,843
| +48% | +$3.5M | 6.17% | 5 |
|
|
2016
Q3 | $5.87M | Buy |
21,729,602
+501,505
| +2% | +$127K | 2.78% | 6 |
|
|
2016
Q2 | $5.09M | Hold |
21,228,097
| – | – | 2.11% | 9 |
|
|
2016
Q1 | $2.42M | Buy |
21,228,097
+5,355,677
| +34% | +$581K | 1.24% | 11 |
|
|
2015
Q4 | $1.79M | Buy |
15,872,420
+13,927,081
| +716% | +$1.97M | 1.01% | 9 |
|
|
2015
Q3 | $370K | Buy |
+1,945,339
| New | +$662K | 0.14% | 10 |
|
Stonehill Capital Management's GCVRZ Position: Q1 2020 in Review
Stonehill Capital Management sold out of Sanofi Contingent Value Rights (GCVRZ) in Q1 2020, closing a stake of 54,410,668 shares — an estimated $46.8M sold.
Stonehill Capital Management first reported a position in GCVRZ in Q3 2015 and held it in 18 quarters. The position peaked at $46.8M in Q4 2019. 2 funds tracked by Wall St. Rank hold GCVRZ as of Q1 2020.
- Stonehill Capital Management reported no remaining Sanofi Contingent Value Rights position as of Q1 2020 after selling out during the quarter.
- Stonehill Capital Management sold 54,410,668 Sanofi Contingent Value Rights shares in Q1 2020, an estimated $46.8M.
- Stonehill Capital Management first reported a position in Sanofi Contingent Value Rights in Q3 2015 and held it in 18 quarters.
- Stonehill Capital Management's Sanofi Contingent Value Rights position peaked at $46.8M in Q4 2019.
- 2 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q1 2020.
Based on Stonehill Capital Management's 13F filing for Q1 2020, filed 15 May 2020.